Kevin D. Freeman

CIK: 0001522478

Transaction Breakdown

Open Market Buys (P)6 (75.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GALT

GALECTIN THERAPEUTICS INC

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

GALT
GALECTIN THERAPEUTICS INC
Jan 16, 2026
Award(A)
Stock option (right to buy)
Direct
60K shares-
GALT
GALECTIN THERAPEUTICS INC
Dec 23, 2025
Purchase(P)
Direct
5.5K shares at avg. $3.55$20K
GALT
GALECTIN THERAPEUTICS INC
Jul 17, 2025
Purchase(P)
Direct
5K shares at avg. $2.90$14K
GALT
GALECTIN THERAPEUTICS INC
Jan 23, 2025
Award(A)
Stock Option (right to buy)
Direct
60K shares-
GALT
GALECTIN THERAPEUTICS INC
Dec 24, 2024
Purchase(P)
Direct
10K shares at avg. $0.81$8K
GALT
GALECTIN THERAPEUTICS INC
Oct 17, 2024
Purchase(P)
Direct
1.3K shares at avg. $2.64$3K
GALT
GALECTIN THERAPEUTICS INC
Oct 16, 2024
Purchase(P)
Direct
5K shares at avg. $2.70$14K
GALT
GALECTIN THERAPEUTICS INC
Oct 16, 2024
Purchase(P)
Indirect
5K shares at avg. $2.70$14K

		Type	Shares	Price		Ownership
Jan 16, 2026	GALT GALECTIN THERAPEUTICS INC	Award(A) Stock option (right to buy)	60,000	-	-	Direct
Dec 23, 2025	GALT GALECTIN THERAPEUTICS INC	Purchase(P)	5,500	$3.55	$19,514	Direct
Jul 17, 2025	GALT GALECTIN THERAPEUTICS INC	Purchase(P)	5,000	$2.90	$14,495	Direct
Jan 23, 2025	GALT GALECTIN THERAPEUTICS INC	Award(A) Stock Option (right to buy)	60,000	-	-	Direct
Dec 24, 2024	GALT GALECTIN THERAPEUTICS INC	Purchase(P)	10,000	$0.81	$8,134	Direct
Oct 17, 2024	GALT GALECTIN THERAPEUTICS INC	Purchase(P)	1,300	$2.64	$3,432	Direct
Oct 16, 2024	GALT GALECTIN THERAPEUTICS INC	Purchase(P)	5,000	$2.70	$13,500	Direct
Oct 16, 2024	GALT GALECTIN THERAPEUTICS INC	Purchase(P)	5,000	$2.70	$13,500	Indirect

1-8 of 8 transactions

About FREEMAN KEVIN D

FREEMAN KEVIN D (SEC CIK 0001522478) files insider reports with the SEC as Director of GALECTIN THERAPEUTICS INC (GALT).

Signal8 holds 9 ownership filings by FREEMAN KEVIN D, all Form 4s, filed between Oct 16, 2024 and Jan 21, 2026. Those filings report 8 transactions, from Oct 16, 2024 to Jan 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on FREEMAN KEVIN D's filings is in NORCROSS, GA.

Recent filings by FREEMAN KEVIN D

Jan 16, 2026: Grant or award of GALT derivative securities (Form 4, code A).
Dec 23, 2025: Open-market purchase of GALT shares (Form 4, code P).
Jul 17, 2025: Open-market purchase of GALT shares (Form 4, code P).
Jan 23, 2025: Grant or award of GALT derivative securities (Form 4, code A).
Dec 24, 2024: Open-market purchase of GALT shares (Form 4, code P).

Other insiders filing for GALECTIN THERAPEUTICS INC (GALT)

Uihlein Richard E, Director
Jamil Khurram, Chief Medical Officer
Shlevin Harold H., Director
Brem Henry, Director
ELDRED KARY, Director
LEWIS JOEL, President and CEO

How to read Form 4 transaction codes